Research menu
Jump to menu

Publications:  Dr Peter Szlosarek

Beddowes E, Spicer J, Chan PY et al. (2017) . Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers.J Clin Oncol vol. 35, (16) 1778-1785.
Chan PY, Hall P, Hay G et al. (2017) . A major responder to ipilimumab and nivolumab in metastatic uveal melanoma with concomitant autoimmunity.Pigment Cell Melanoma Res vol. 30, (6) 558-562.
Szlosarek PW, Steele JP, Nolan L et al. (2017) . Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial.JAMA Oncol vol. 3, (1) 58-66.
Szlosarek PW, Steele JP, Nolan L et al. (2017) . Arginine deprivation with pegylated arginine deiminase in patients with argininosuccinate synthetase 1-deficient malignant pleural mesothelioma a randomized clinical trial.JAMA Oncology vol. 3, (1) E1-E9.
Szyszko TA, Bomalaski JS, Goh V et al. (2016) . TRAP substudy: assessment of 18-FLT PET/CT to examine tumour proliferation in patients with ASS1-deficient thoracic cancers treated with arginine deiminase (ADI)-PEG20, pemetrexed and cisplatin. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. vol. 43, S354-S354.
Locke M, Ghazaly E, Freitas MO et al. (2016) . Inhibition of the Polyamine Synthesis Pathway Is Synthetically Lethal with Loss of Argininosuccinate Synthase 1.Cell Reports vol. 16, (6) 1604-1613.
Karydis I, Chan PY, Wheater M et al. (2016) . Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma.Oncoimmunology vol. 5, (5)
Szyszko TA, Yip C, Szlosarek P et al. (2016) . The role of new PET tracers for lung cancer.Lung cancer (Amsterdam, Netherlands) vol. 94, 7-14.
Burrows N, Cane G, Robson M et al. (2016) . Hypoxia-induced nitric oxide production and tumour perfusion is inhibited by pegylated arginine deiminase (ADI-PEG20).Sci Rep vol. 6,
Klionsky DJ, Abdelmohsen K, Abe A et al. (2016) . Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).Autophagy vol. 12, (1) 1-222.
Nathan P, Cohen V, Coupland S et al. (2015) . Uveal Melanoma UK National Guidelines.Eur J Cancer vol. 51, (16) 2404-2412.
Phillips MM, Khadeir R, Tookman L et al. (2015) . Macrophages promote resistance to pegylated arginine deiminase in malignant pleural mesothelioma. CANCER RESEARCH. vol. 75,
Pazmandi J, O'Neill KS, Scheck AC et al. (2015) . The ketogenic diet alters the expression of microRNAs that play key roles in tumor development. CANCER RESEARCH. vol. 75,
Khadeir RS, Phillips MM, Sgoo MS et al. (2015) . Widespread deficiency of ASS1 in uveal melanoma and sensitivity to pegylated arginine deiminase. CANCER RESEARCH. vol. 75,
Miraki-Moud F, Ghazaly E, Ariza-McNaughton L et al. (2015) . Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo.Blood vol. 125, (26) 4060-4068.
Szlosarek PW, Spicer JF, Szyszko T et al. (2015) . Phase I study of ADI-PEG 20 in combination with pemetrexed and cisplatin (TRAP) in patients with ASS1-deficient mesothelioma and non-squamous lung cancer. JOURNAL OF CLINICAL ONCOLOGY. vol. 33,
Szlosarek PW, Lee S, Pollard PJ (2014) . Rewiring mitochondrial pyruvate metabolism: switching off the light in cancer cells?.Mol Cell vol. 56, (3) 343-344.
Cutts R, Jithesh PV, Delage B et al. (2014) . Gene expression analysis of argininosuccinate synthetase loss and the effects of pegylated arginine deiminase in malignant pleural mesothelioma. CANCER RESEARCH. vol. 74,
Szlosarek PW (2014) . Arginine deprivation and autophagic cell death in cancer.Proc Natl Acad Sci U S A vol. 111, (39) 14015-14016.
Ghazaly EA, Luong P, Chmielewska-Kassassir M et al. (2014) . Metabolomic analysis of pegylated arginine deiminase treatment in patients with malignant pleural mesothelioma. JOURNAL OF CLINICAL ONCOLOGY. vol. 32,
Szlosarek PW, Steele JP, Nolan L et al. (2014) . Randomized trial of arginine deprivation with pegylated arginine deiminase in patients with malignant pleural mesothelioma. JOURNAL OF CLINICAL ONCOLOGY. vol. 32,
Allen MD, Luong P, Hudson C et al. (2014) . Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging.Cancer Res vol. 74, (3) 896-907.
Rintoul RC, Rassl DM, Maskell N et al. (2014) . MesobanK - a UK based bioresource for malignant mesothelioma.LUNG CANCER vol. 83, S82-S82.
Phillips MM, Sheaff MT, Szlosarek PW (2013) . Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges.Cancer Res Treat vol. 45, (4) 251-262.
Miraki-Moud F, Ariza-McNaughton L, Ghazaly EA et al. (2013) . Arginine Deprivation With Pegylated Arginine Deiminase Induces Death Of Acute Myeloid Leukaemia Cells In Vivo. BLOOD. vol. 122,
Sommerlad M, Purdie K, Rizvi H et al. (2013) . Vemurafenib, photosensitivity and human papillomavirus infection: an emerging story. BRITISH JOURNAL OF DERMATOLOGY. vol. 169, 9-9.
Zheng L, MacKenzie ED, Karim SA et al. (2013) . Reversed argininosuccinate lyase activity in fumarate hydratase-deficient cancer cells.Cancer Metab vol. 1, (1)
Szlosarek PW, Luong P, Phillips MM et al. (2013) . Metabolic response to pegylated arginine deiminase in mesothelioma with promoter methylation of argininosuccinate synthetase.J Clin Oncol vol. 31, (7) e111-e113.
Syed N, Langer J, Janczar K et al. (2013) . Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma.Cell Death Dis vol. 4,
Matin RN, Szlosarek P, McGregor JM et al. (2013) . Synchronous melanoma and renal carcinoma: a clinicopathological study of five cases.Clin Exp Dermatol vol. 38, (1) 47-49.
Lewis A, Hough N, Woolf DK et al. (2013) . Systemic therapy in the management of non small cell lung cancer (NSCLC): The real world experience.LUNG CANCER vol. 79, S17-S17.
Hough N, Lewis A, Woolf DK et al. (2013) . Three years experience of chemotherapy for small cell lung cancer at a tertiary referral centre.LUNG CANCER vol. 79, S65-S65.
Coward JIG, Ding N-L, Feakins R et al. (2012) . Chemotherapy-induced bowel obstruction in small cell lung cancer: a case report.Med Oncol vol. 29, (4) 2623-2625.
Delage B, Luong P, Maharaj L et al. (2012) . Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis.Cell Death Dis vol. 3,
Hatzimichael E, Dasoula A, Syed N et al. (2012) . Epigenetic inactivation to target the arginine biosynthetic pathway in multiple myeloma. JOURNAL OF CLINICAL ONCOLOGY. vol. 30,
Wang H, Lee S, Nigro CL et al. (2012) . NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity.Br J Cancer vol. 106, (8) 1446-1452.
Matin RN, Gonzalez D, Thompson L et al. (2012) . KIT and BRAF mutational status in a patient with a synchronous lentigo maligna melanoma and a gastrointestinal stromal tumor.Am J Clin Dermatol vol. 13, (1) 64-65.
Syed N, Coley HM, Sehouli J et al. (2011) . Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer.Cancer Res vol. 71, (9) 3317-3327.
Allen M, Syed N, Luong F et al. (2011) . Epigenetic silencing of argininosuccinate synthetase renders human bladder cancer cells sensitive to pegylated arginine deiminase.CANCER RESEARCH vol. 71,
Szlosarek PW, Luong F, Clear A et al. (2011) . Pegylated arginine deiminase (ADI-PEG20) as a potential novel therapy for argininosuccinate synthetase-deficient acute myeloid leukemia.CANCER RESEARCH vol. 71,
Syed N, O'Neilli K, Hughes M et al. (2011) . Transcriptional silencing disrupts two levels of arginine biosynthesis in glioblastoma multiforme: a novel, targeted therapeutic strategy for high grade gliomas.CANCER RESEARCH vol. 71,
Delage B, Fennell DA, Nicholson L et al. (2010) . Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer.Int J Cancer vol. 126, (12) 2762-2772.
Nicholson LJ, Smith PR, Hiller L et al. (2009) . Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer.Int J Cancer vol. 125, (6) 1454-1463.
Matin RN, Harwood CA, McAndrew L et al. (2009) . A clinicopathological study of cases of synchronous melanoma and renal carcinoma. BRITISH JOURNAL OF DERMATOLOGY. vol. 161, 19-19.
Lim SL, Smith P, Syed N et al. (2008) . Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer.BRIT J CANCER vol. 98, (8) 1452-1456.
Szlosarek PW, Grimshaw MJ, Wilbanks GD et al. (2007) . Aberrant regulation of argininosuccinate synthetase by TNF-alpha in human epithelial ovarian cancer.Int J Cancer vol. 121, (1) 6-11.
Szlosarek PW, Klabatsa A, Pallaska A et al. (2006) . In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion.Clin Cancer Res vol. 12, (23) 7126-7131.
Szlosarek PW, Fennell DA, Rudd RM et al. (2006) . A randomized phase II trial of pegylated arginine deaminase (ADI-PEG 20) in patients with malignant pleural mesothelioma.LUNG CANCER vol. 54, S54-S54.
Szlosarek P, Charles KA, Balkwill FR (2006) . Tumour necrosis factor-alpha as a tumour promoter.Eur J Cancer vol. 42, (6) 745-750.
Szlosarek PW, Grimshaw MJ, Kulbe H et al. (2006) . Expression and regulation of tumor necrosis factor alpha in normal and malignant ovarian epithelium.Mol Cancer Ther vol. 5, (2) 382-390.
Kulbe H, Hagemann T, Szlosarek PW et al. (2005) . The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells.Cancer Res vol. 65, (22) 10355-10362.
Szlosarek PW, Grimshaw MJ, Wilbanks GD et al. (2004) . Regulation and expression of argininosuccinate synthetase in human ovarian cancer. BRITISH JOURNAL OF CANCER. vol. 91, S57-S57.
Szlosarek P, Balkwill F (2004) . The inflammatory cytokine network of epithelial cancer: therapeutic implications.Novartis Found Symp vol. 256, 227-237.
Szlosarek PW, Balkwill FR (2003) . Tumour necrosis factor alpha: a potential target for the therapy of solid tumours.Lancet Oncol vol. 4, (9) 565-573.
Nicholson S, Guile K, John J et al. (2003) . A randomized phase II trial of SRL172 (Mycobacterium vaccae) +/- low-dose interleukin-2 in the treatment of metastatic malignant melanoma.MELANOMA RES vol. 13, (4) 389-393.
Szlosarek PW (2001) . Recent advances in palliative care - United Kingdom continues to lead in palliative care.BRIT MED J vol. 322, (7280) 234-234.
Return to top